Keyword: Valeant Pharmaceuticals
Intellia clinical head to be Casebia’s first CMO; Ferring CSO to take over for retiring board president; and Harpoon names new CFO and CSO.
Xenon Pharmaceuticals is taking a stab at repurposing GlaxoSmithKline's ezogabine for a rare, difficult-to-treat form of pediatric epilepsy.
Lilly’s oncology chief is retiring; a GSK vet is launching a Chinese public health startup; and Gilead’s R&D chief is going back to his roots.
Kala Pharmaceuticals has filed to list on Nasdaq to equip itself to file for approvals of corticosteroid nanosuspension KPI-121 in two indications.
A trio of top execs exit embattled Valeant, Genentech promotes Bill Anderson to CEO, and Alexion replaces its CEO and CFO amid an internal Soliris sales probe. Plus more hirings, firings and retirings throughout the industry.
Valeant ended the day down 12% yesterday on news coming out of Bloomberg that its former top execs are under a criminal probe from federal prosecutors.
This week an FDA panel backed Valeant's skin drug brodalumab and then the regulator gave the thumbs up for an oral version of its constipation drug Relistor. But its good fortune has come to an end as the FDA has today rejected an approval for its experimental eye drug.
Troubled Canadian specialty pharma company Valeant has won U.S. approval for a new oral formulation of the previously injectable-only med Relistor for certain forms of constipation in what could push the drug into blockbuster territory.